
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Elutia Inc. (ELUT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ELUT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $6.5
1 Year Target Price $6.5
2 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.17% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 98.78M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 2 | Beta 0.88 | 52 Weeks Range 1.61 - 5.12 | Updated Date 08/29/2025 |
52 Weeks Range 1.61 - 5.12 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.19 | Actual -0.26 |
Profitability
Profit Margin -90.01% | Operating Margin (TTM) -93.74% |
Management Effectiveness
Return on Assets (TTM) -37.27% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 118522143 | Price to Sales(TTM) 4.17 |
Enterprise Value 118522143 | Price to Sales(TTM) 4.17 | ||
Enterprise Value to Revenue 5 | Enterprise Value to EBITDA -3.32 | Shares Outstanding 38081900 | Shares Floating 15385269 |
Shares Outstanding 38081900 | Shares Floating 15385269 | ||
Percent Insiders 2.2 | Percent Institutions 70.65 |
Upturn AI SWOT
Elutia Inc.

Company Overview
History and Background
Elutia Inc., formerly known as SurModics, Inc., was founded in 1979. It initially focused on surface modification technologies before evolving into a medical device company. It transitioned after selling its In Vitro Diagnostics and SurModics Pharmaceuticals businesses to focus on its Preecludia and Biorez technologies in 2024. The company rebranded as Elutia Inc. to mark its renewed focus.
Core Business Areas
- Biorez: BioREZ is a reinforced soft tissue repair technology utilizing a proprietary polymer composite. The Biorez platform utilizes a unique polymer that exhibits superior biointegration when implanted in vivo.
- Drug Delivery: Elutia's drug delivery technologies are designed to provide sustained and localized drug release to target tissues. These technologies enhance the efficacy and safety of therapeutic agents.
- Preecludia: Preecludia is a platform technology for anti-thrombotic and anti-inflammatory therapies. It is a key focus for Elutia, aimed at reducing blood clots and inflammation related to medical devices.
Leadership and Structure
Elutia Inc.'s leadership team consists of a CEO, CFO, and other key executives overseeing various departments like R&D, marketing, and operations. The organizational structure is hierarchical, with clear lines of reporting and accountability. David A. Dullum is the CEO and President.
Top Products and Market Share
Key Offerings
- BioREZ Platform: BioREZ offers a solution for soft tissue repair. Market share data for BioREZ is emerging; revenue attributable to Biorez in Q1 2024 was $1.3 million. Competitors include companies offering collagen scaffolds and other soft tissue repair products, such as Stryker and Smith & Nephew.
- Preecludia Platform: Preecludia technology is designed to improve the biocompatibility of medical devices to reduce the risk of thrombosis and inflammation. Market share data specific to Preecludia is not readily available. Competitors in anti-thrombotic coating technologies include Medtronic, Abbott, and Boston Scientific.
- Sustained Drug Delivery: Elutia focuses on drug delivery technologies for various applications including localized drug release for medical devices. Competitors: Durect, Alkermes, and Vectura.
Market Dynamics
Industry Overview
The medical device industry is characterized by continuous innovation, stringent regulatory requirements, and high competition. Key trends include the development of minimally invasive procedures, personalized medicine, and advanced biomaterials.
Positioning
Elutia Inc. is positioned as an innovator in biomaterials and drug delivery, focusing on high-growth areas within the medical device industry. Its competitive advantages include proprietary technologies and a focus on addressing unmet clinical needs.
Total Addressable Market (TAM)
The global medical device market is estimated to reach hundreds of billions of dollars. Elutia Inc.'s focus on specialized areas such as anti-thrombotic coatings and soft tissue repair positions it to capture a portion of this TAM. The TAM for soft tissue repair and anti-thrombotic coatings combined could be in the billions of dollars annually.
Upturn SWOT Analysis
Strengths
- Proprietary Technology Platforms (Preecludia, BioREZ)
- Expertise in Biomaterials and Drug Delivery
- Focus on high-growth medical device segments
- Strong R&D capabilities
- Experienced Management Team
Weaknesses
- Limited commercial infrastructure as a smaller company
- Dependence on regulatory approvals for new products
- Cash burn and need for additional financing
- Revenue concentration from limited products
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Acquisition of complementary technologies
- Increasing demand for advanced biomaterials
- Growing market for minimally invasive procedures
Threats
- Intense competition from larger medical device companies
- Changing regulatory landscape
- Product liability risks
- Economic downturn affecting healthcare spending
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
- JNJ
Competitive Landscape
Elutia Inc. faces strong competition from larger, more established medical device companies. Its competitive advantages lie in its proprietary technologies and specialized expertise. However, its limited commercial infrastructure and financial resources pose challenges.
Growth Trajectory and Initiatives
Historical Growth: Elutia's growth has been driven by innovation in biomaterials. Divestiture of businesses, including SurModics Pharmaceuiticals has affected revenue.
Future Projections: Future growth depends on regulatory approvals and successful commercialization of its Preecludia and BioREZ technologies. Analysts forecast increased revenue in the next few years.
Recent Initiatives: Recent strategic initiatives include rebranding, focusing on Preecludia and BioREZ platforms, and optimizing its operations.
Summary
Elutia is a medical device company with specialized biomaterial expertise and proprietary technologies but faces stiff competition from established players and needs additional funding to support operations. Successful commercialization of its BioREZ and Preecludia platforms is critical for future growth. Elutia must manage its cash burn and secure regulatory approvals to succeed. With the right execution, Elutia can become a strong company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Earnings call transcripts
- Press releases
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice, and investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elutia Inc.
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 2023-09-07 | Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 51 | Website https://elutia.com |
Full time employees 51 | Website https://elutia.com |
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.